Hear from Dr. Papp about the management of psoriasis and Chronic Spontaneous Urticaria (CSU)

Dr Papp is a Member of the College of Physicians and Surgeons of Ontario, a Fellow of the Royal College of Physicians and Surgeons of Canada, and a Fellow of the American Academy of Dermatology and he is the founder of Probity Clinical Research.



 

Anti-IL 17 blockers in psoriasis

Can you define CSU?

Omalizumab, and the impact it has had on treating the disease?

Secukinumab 5 yr data


This publication is sponsored by an educational grant by Novartis Pharmaceuticals Australia Pty Ltd. The content is entirely independent and based on published studies and the authors’ opinions. It may not reflect the views of Novartis. Please consult the Xolair and Cosentyx full product information before prescribing.

        Novartis Pharmaceuticals Pty Limited.
        54 Waterloo Road, Macquarie Park NSW 2113. ABN 18 004 244 160 Ph. (02) 9805 3555. 
        For medical enquiries please contact 1800 671 203 (phone) or email medinfo.phauno@novartis.com